Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck zetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2020
-1
Period ended Dec 31, 2020
Change on a year earlier
-107.1%
14 in FY2019
History
5 years
Since FY2016
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | -1 | -107.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 14 | -68.9% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 45 | -87.2% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 352 | -77.8% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 1,588 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up zetia (ezetimibe, legacy pre-organon spin-off) — u.s. sales ($m)
Cite this data
StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_zetia_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.